Abstract No. 517 Cheaper isn’t always cheapest:cost analysis of Y-90 vs transarterial chemoembolization for treatment of hepatocellular carcinoma

Desai, Akash; McCabe, Bridgette E.; Natarajan, B.

doi:10.1016/j.jvir.2018.12.598

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TACE is also readily covered by Medicare and Medicaid. 51 Unfortunately, the high one-time cost and inconsistent insurance coverage make TARE cost-prohibitive for some patients. However, considering the increased frequency of TACE sessions, associated overnight hospital stays, and costs associated with adverse events relative to a single TACE procedure, the cumulative costs on a per-lesion basis are likely to be comparable.…”

Section: Economic Factorsmentioning

confidence: 99%

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

Behzadi,

Haghani,

D'Souza

et al. 2024

Semin intervent Radiol

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are common liver-directed therapies (LDTs) for unresectable HCC. While both deliver intra-arterial treatment directly to the site of the tumor, they differ in mechanisms of action and side effects. Several studies have compared their side effect profile, time to progression, and overall survival data, but often these lack practical considerations when choosing which treatment modality to use. Many factors can impact operator's choice for treatment, and the choice depends on treatment availability, cost, insurance coverage, operator's comfort level, patient-specific factors, tumor location, tumor biology, and disease stage. This review discusses survival data, time to progression data, as well as more practical patient and tumor characteristics for personalized LDT with TACE or TARE.

show abstract

Section: Economic Factorsmentioning

confidence: 99%

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

Behzadi,

Haghani,

D'Souza

et al. 2024

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…The cost for Y90 was reported as an average of $32,500. 9 However, data comparing the cost and effectiveness of Y90 and SBRT are limited.…”

mentioning

confidence: 99%

SBRT vs. Y90

deBettencourt,

Liu,

Cotler

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: Stereotactic Body Radiotherapy (SBRT) and Yttrium-90 (Y90) are among the ablative therapies used as treatment options for localized hepatocellular carcinoma (HCC). To date, direct comparisons of the 2 modalities’ outcomes and costs are lacking. This study aimed to analyze demographic, treatment, and cost information for patients with HCC treated with SBRT and Y90. Methods: Patients with HCC treated with SBRT or Y90 radioembolization between January 2018 and January 2020 at one institution were retrospectively reviewed. Demographic and treatment data were compared utilizing χ2 tests. Kaplan-Meier curves and log-rank tests were applied to compare overall survival and progression-free survival in different treatment groups. Cox proportional hazard models were applied to analyze the unadjusted and adjusted survival differences. Ten SBRT and 10 Y90 patients were randomly selected for Medicare cost analysis. Results: Sixty-three patients received Y90, and 21 received SBRT. On univariable and multivariable analysis, there was no significant difference in overall survival or progression-free survival between the Y90 and SBRT cohorts. SBRT patients had higher American Joint Committee on Cancer staging (P=0.039), greater tumor size (4.07 vs. 2.96 cm, P=0.013), and greater rates of prior liver-directed therapy (71.4% SBRT vs. 12.7% Y90, P<0.001). The average cost for SBRT was $15,148, and Y90 was $41,360. Conclusions: SBRT and Y90 are effective therapies in the treatment of HCC, specifically having similar overall survival and progression-free survival. Y90 was found to have a significantly higher cost than SBRT. This study demonstrates the need for prospective studies to assess these modalities in treating HCC.

show abstract

Rapid separation, purification of 90Sr and feasibility studies for the preparation of 90Y resin microsphere brachytherapy source from FBTR irradiated fuel dissolver solution

Saha,

Vithya,

Kalaiarasu

et al. 2024

J Radioanal Nucl Chem

View full text Add to dashboard Cite

Abstract No. 517 Cheaper isn’t always cheapest:cost analysis of Y-90 vs transarterial chemoembolization for treatment of hepatocellular carcinoma

Cited by 3 publications

References 0 publications

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

SBRT vs. Y90

Rapid separation, purification of 90Sr and feasibility studies for the preparation of 90Y resin microsphere brachytherapy source from FBTR irradiated fuel dissolver solution

Contact Info

Product

Resources

About